Biotech Values

[corky]

Oct 27 (Reuters) - Vertex Pharmaceuticals Inc. (VRTX.O: Quote, Profile, Research) on Friday said some patients in early-stage trials of its experimental treatment for hepatitis C virus continued to have the condition in one of the combination therapies.

The treatment, telaprevir, is being used in combination with pegylated interferon alfa-2a, both with and without ribavirin.

In a statement, the company said some of these patients continued to have undetectable levels of the virus after stopping the therapy in combination with ribavirin.

When taken without ribavirin, the therapy suppressed both wild-type hepatitis C virus and resistant variants. (Reporting by Saumyadeb Chakrabarty in Bangalore)